IGF1 and neoplasm: Our data reveal CHK1 as a potential partner for co-inhibition with IGF blockade; we suggest that the efficacy of this combination may be most appropriately tested in ATM null tumours given our recent identification of ATM loss as a candidate biomarker for sensitivity to IGF axis blockade [14].